Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States

Background and objectiveThe EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering bot...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andong Li, Meiyu Wu, Ouyang Xie, Heng Xiang, Kehui Meng, Chongqing Tan, Long Wang, Xiaomin Wan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-09-01
Colecção:	Frontiers in Immunology
Assuntos:	enfortumab vedotin pembrolizumab bladder cancer cost-effectiveness the United States
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1464092/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!